絞り込み

16735

広告

京大霊長類研の教授ら4人 5億円余を不正支出 大学が報告書 (NHK)

サルの研究で世界的に有名な京都大学霊長類研究所の教授ら4人が、研究費5億円余りを不正に支出していたとする調査報告書を京都大学がまとめたことが分かりました。 研究...

  1. ノーベル賞受賞の物性物理の泰斗、アンダー...
  2. ノーベル賞受賞の物性物理の泰斗、アンダー...
  3. 海底の岩、人間の腸内並み微生物 (デイリ...
  4. 新型コロナウイルス感染症の患者等の発生に...

ニュース一覧

1338件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo.

Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations.

An -Amplified Cervical Squamous Cell Carcinoma Patient with Pulmonary Metastasis Benefits from Afatinib: A Case Report.

Synthesis, antitumor activity, and molecular docking study of 2-cyclopentyloxyanisole derivatives: mechanistic study of enzyme inhibition.

Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance.

Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.

Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag).

Phase II trial of afatinib in elderly patients over 75 years of age with EGFR mutation positive NSCLC.

Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC.

A phase II study of first-line low-dose afatinib in patients with EGFR mutated non-small-cell lung cancer (KTORG1402).

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.

Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study.

Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells.

Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study).

Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?

Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: Preliminary results.

Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります